» Articles » PMID: 37373131

In the Pursuit of Metabolic Markers of Systemic Sclerosis-Plasma Adiponectin and Omentin-1 in Monitoring the Course of the Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jun 28
PMID 37373131
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic sclerosis (SSc) is a connective tissue disease leading to cutaneous and visceral fibrosis. Pathological features of SSc include immune dysregulation, vasculopathy, and impaired angiogenesis. Adipokines act as cytokines and hormones and are involved in various pathological processes, including metabolic disorders, inflammation, vasculopathy, and fibrosis. This study aimed to determine the level of omentin-1 and adiponectin to evaluate their potential role in the pathogenesis of SSc. We assessed serum omentin-1 and adiponectin as well as metabolic parameters in 58 patients with SSc and 30 healthy controls. The follow-up was performed in SSc individuals. Omentin-1 levels were significantly higher in SSc individuals as compared to the controls. In post-hoc analysis, omentin-1 was higher in the group with disease duration ≥7 years than in the control group. A positive correlation was noted between disease duration and both adipokines and increased with longer disease duration. However, there were no correlations between selected adipokines and metabolic parameters. Enhanced omentin-1 levels and higher levels of omentin-1 in patients with longer disease duration may suggest that omentin-1 is involved in the pathomechanisms of SSc as its concentrations are not directly related to BMI, age, and insulin resistance.

References
1.
Miura S, Asano Y, Saigusa R, Yamashita T, Taniguchi T, Takahashi T . Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis. J Dermatol. 2015; 42(5):461-6. DOI: 10.1111/1346-8138.12824. View

2.
Sanchez-Perez H, Tejera-Segura B, de Vera-Gonzalez A, Gonzalez-Delgado A, Olmos J, Hernandez J . Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. Clin Exp Rheumatol. 2017; 35(6):885-892. View

3.
Lau W, Ohashi K, Wang Y, Ogawa H, Murohara T, Ma X . Role of Adipokines in Cardiovascular Disease. Circ J. 2017; 81(7):920-928. DOI: 10.1253/circj.CJ-17-0458. View

4.
Volkmann E, Andreasson K, Smith V . Systemic sclerosis. Lancet. 2022; 401(10373):304-318. PMC: 9892343. DOI: 10.1016/S0140-6736(22)01692-0. View

5.
Giralt M, Cereijo R, Villarroya F . Adipokines and the Endocrine Role of Adipose Tissues. Handb Exp Pharmacol. 2015; 233:265-82. DOI: 10.1007/164_2015_6. View